News & Articles

Detecting lung cancer early with advanced flow cytometry

Our Most Recent News, Events, Press Releases

Latest Information

Latest Updates

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

SAN ANTONIO, Texas (Jan. 22, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian Patent Office (IP Australia), has accepted bioAffinity’s patent application for the method of predicting the likelihood of lung cancer used by the CyPath® Lung diagnostic test for early-stage lung cancer. The Australian patent application, titled “Detection of Early-Stage Lung Cancer in Sputum Using Automated Flow Cytometry and Machine Learning,” will be an important addition to bioAffinity Technologies’ patent portfolio, which includes 17 awarded U.S. and foreign patents and 38 pending patent applications related to its diagnostic platform and cancer treatment...
Read More

bioAffinity Technologies Set for Continued Expansion in 2025

Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues  SAN ANTONIO, TX (Dec. 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests...
Full Catalog of Prior Articles, News, Events, and Press Releases

Prior Articles

News & Articles

Precision Pathology laboratory Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test is sold by Precision Pathology Laboratory Services, a bioAffinity Technologies company,  as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ

Subscribe for News from bioAffinity Technologies